Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
PaperCitations, authors & open-access status
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 155 citations, 2021 year and hybrid oa status.
155
Citations
2021
Year
hybrid
OA Status